– Global collaboration aims to deliver on the promise of integrated cancer medicine by bringing insights across multiple diagnostic modalities – at scale – to clinical and biopharma customers.
– Support continuum of care by combining data from the GE Healthcare Edison platform and the SOPHiA DDM™ cloud-based platform.
– Advance standardization of data to improve quality of care through the digitalization of the oncology patient journey.
GE Healthcare and SOPHiA GENETICS today announced that they have signed a letter of intent to collaborate on advancing cancer care, with the goal of better targeting and matching treatments to each patient’s genomic profile and cancer type, helping to ensure the most effective and personalized treatment.
The companies aim to develop new artificial intelligence (AI)-powered analytics and workflow solutions to serve both the clinical and biopharma markets. They’ll be deploying GE Healthcare’s extensive medical imaging and monitoring capabilities and Edison platform-enabled data aggregation with the SOPHiA DDM™ cloud-based software-as-a-service analytics genomic insights platform and related solutions, which are available in more than 750 hospitals, laboratories and biopharma companies.
GE Healthcare has deep expertise in clinical workflows, deep learning AI algorithms for image reconstruction and image segmentation, analytics and standardization, while SOPHiA GENETICS is a pioneer in data-driven medicine. Their cloud-based software-as-a-service analytics platform uses AI and machine learning to generate actionable insights for clinicians and researchers from complex multimodal datasets. The companies aim to break down the data silos across instruments and sites that so often delay or even prevent patients from getting the most appropriate treatment both in cancer and in other diseases.
As cases of cancer continue to rise and are predicted to reach 29.5 million new cases per year by 2040,1 there is a growing demand for data-driven medicine, both for clinical practice and clinical trials. GE Healthcare is utilizing its Edison platform to integrate data from diverse sources, such as electronic health records (EHR) and radiology information systems (RIS), imaging and other medical device data. This integrated data can be used to develop and deploy AI enabled solutions to help simplify oncology patient workflows, better understand increasingly complicated clinical patient data, and compare data from patient to patient.
“The integration of genomics-based artificial intelligence into oncology workflow solutions would be a major breakthrough for integrated cancer medicine and for future clinical research, which increasingly depend on the ability to select those patients most likely to respond to new therapies,” said Jan Makela, President & CEO, Imaging at GE Healthcare. “This collaboration represents anotherstep in GE Healthcare’s vision of making precision health—more efficient and personalized care—a reality.”
“By bringing together our global platform and insights-sharing network with GE Healthcare’s international reach and cutting-edge products, healthcare professionals will be able to leverage their expertise and work together for the benefit of patients all over the world. Cancer patients will be able to receive equal access to better diagnoses and treatments through secure data pooling and knowledge sharing, unlocking the promise of data-driven medicine at scale,” said Jurgi Camblong, co-founder and CEO, SOPHiA GENETICS.
Next-generation sequencing (NGS) is rapidly becoming a new standard of care in cancer diagnostics, particularly as novel therapies require genomic information to be prescribed in a personalized way. Today, these sets of information and insights are often bespoke and difficult for clinicians to easily and quickly obtain and recall along the patient care journey.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.
